Buprenorphine has potent kappa opioid receptor antagonist activity.
Buprenorphine was studied for its effects on urinary output to determine if it was an agonist, partial agonist, or antagonist at the kappa receptor. Buprenorphine was a potent antagonist of bremazocine-induced urination and had no kappa agonist activity. Thus, the high affinity that buprenorphine has for the kappa receptor results in potent kappa receptor antagonist activity in vivo.
Leander
J D
JD
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.
D000818:Animals; D001575:Benzomorphans / Q000494:pharmacology; D002047:Buprenorphine / Q000494:pharmacology*; D004231:Diuresis / Q000187:drug effects; D004338:Drug Combinations; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000145:classification / Q000187:drug effects*
D001575:Benzomorphans; D004338:Drug Combinations; D011957:Receptors, Opioid; D002047:Buprenorphine; D009271:Naltrexone; C024524:beta-funaltrexamine; C027248:bremazocine